F. Cacace

High-Risk Acute Myeloid Leukemia: A Pediatric Prospective

K. Mahadeo, F. Tambaro, W. Wierda, 2022, Biomedicines.

Eltrombopag for post-transplant cytopenias due to poor graft function

A. Risitano, F. Pane, P. Ricci, 2019, Bone Marrow Transplantation.

Ibrutinib as salvage therapy in mantle cell lymphoma with central nervous system involvement in a pretreated unfit patient

F. Pane, C. Mainolfi, M. Notarangelo, 2018, Leukemia & lymphoma.

Anti-complement Treatment for Paroxysmal Nocturnal Hemoglobinuria: Time for Proximal Complement Inhibition? A Position Paper From the SAAWP of the EBMT

P. Scheinberg, A. Risitano, R. Calado, 2019, Front. Immunol..

Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia.

G. Mufti, S. Iacobelli, N. Russell, 2022, The New England journal of medicine.

The TKI Era in Chronic Leukemias

K. Mahadeo, F. Tambaro, W. Wierda, 2021, Pharmaceutics.

Categorizing hematological response to eculizumab in paroxysmal nocturnal hemoglobinuria: a multicenter real-life study

P. Scheinberg, A. Risitano, R. Calado, 2021, Bone Marrow Transplantation.

Hematological Response to Eculizumab in Paroxysmal Nocturnal Hemoglobinuria: Application of a Novel Classification to Identify Unmet Clinical Needs and Future Clinical Goals

P. Scheinberg, A. Risitano, R. Calado, 2019, Blood.